Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.1
(-21.67%)
SEK 0.1
(-21.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -12.12 Million SEK | 67.8% |
| 2022 | -37.66 Million SEK | 8.39% |
| 2021 | -41.11 Million SEK | -394.68% |
| 2020 | -8.31 Million SEK | -64.99% |
| 2019 | -5.03 Million SEK | -33.7% |
| 2018 | -3.76 Million SEK | 99.88% |
| 2017 | -3.03 Billion SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -415 Thousand SEK | 94.4% |
| 2024 Q1 | -7.41 Million SEK | 1.87% |
| 2023 FY | -12.12 Million SEK | 67.8% |
| 2023 Q2 | 7.13 Million SEK | 204.34% |
| 2023 Q1 | -6.83 Million SEK | 25.5% |
| 2023 Q4 | -7.55 Million SEK | -55.22% |
| 2023 Q3 | -4.86 Million SEK | -168.25% |
| 2022 Q3 | -6.84 Million SEK | 45.89% |
| 2022 Q4 | -9.17 Million SEK | -34.09% |
| 2022 Q2 | -12.64 Million SEK | -40.68% |
| 2022 Q1 | -8.99 Million SEK | 37.66% |
| 2022 FY | -37.66 Million SEK | 8.39% |
| 2021 FY | -41.11 Million SEK | -394.68% |
| 2021 Q2 | -10.37 Million SEK | -112.38% |
| 2021 Q4 | -14.42 Million SEK | -26.12% |
| 2021 Q1 | -4.88 Million SEK | -1.77% |
| 2021 Q3 | -11.43 Million SEK | -10.21% |
| 2020 Q1 | -907 Thousand SEK | 0.0% |
| 2020 FY | -8.31 Million SEK | -64.99% |
| 2020 Q4 | -4.8 Million SEK | -499.25% |
| 2020 Q3 | -801 Thousand SEK | 48.69% |
| 2020 Q2 | -1.56 Million SEK | -72.11% |
| 2019 FY | -5.03 Million SEK | -33.7% |
| 2018 FY | -3.76 Million SEK | 99.88% |
| 2017 FY | -3.03 Billion SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 73.52% |
| Biovica International AB (publ) | -124.82 Million SEK | 90.284% |
| Cantargia AB (publ) | -280.02 Million SEK | 95.669% |
| CombiGene AB (publ) | -35.66 Million SEK | 65.995% |
| Cyxone AB (publ) | -22.98 Million SEK | 47.244% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -3.853% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 26.04% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 86.731% |
| Fluicell AB (publ) | -26.55 Million SEK | 54.327% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 90.145% |
| Mendus AB (publ) | -101.61 Million SEK | 88.065% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 67.284% |
| I-Tech AB | 20.2 Million SEK | 160.031% |
| Intervacc AB (publ) | -102.85 Million SEK | 88.208% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 199.663% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 32.234% |
| OncoZenge AB (publ) | -15.9 Million SEK | 23.733% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -2668.95% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 96.876% |
| Lipum AB (publ) | -37.17 Million SEK | 67.379% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 95.121% |
| Ziccum AB (publ) | -21.41 Million SEK | 43.359% |
| BioArctic AB (publ) | 229.24 Million SEK | 105.29% |
| Genovis AB (publ.) | 61.5 Million SEK | 119.72% |
| Camurus AB (publ) | 431.44 Million SEK | 102.811% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 93.18% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 78.656% |
| Aptahem AB (publ) | -11.11 Million SEK | -9.135% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 96.1% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 93.25% |
| Kancera AB (publ) | -64.88 Million SEK | 81.31% |
| Saniona AB (publ) | -95.81 Million SEK | 87.342% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 71.276% |
| AcouSort AB (publ) | -17.08 Million SEK | 29.03% |
| Xintela AB (publ) | -54.08 Million SEK | 77.575% |
| Abliva AB (publ) | -95.5 Million SEK | 87.302% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 325.176% |
| Amniotics AB (publ) | -30.87 Million SEK | 60.713% |
| 2cureX AB (publ) | -32.51 Million SEK | 62.704% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 5.457% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 97.398% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.542% |
| Biosergen AB | -27.03 Million SEK | 55.143% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 26.599% |
| Corline Biomedical AB | -1.8 Million SEK | -570.426% |
| NextCell Pharma AB | -41.95 Million SEK | 71.096% |
| Nanologica AB (publ) | -75.15 Million SEK | 83.863% |
| LIDDS AB (publ) | -40.2 Million SEK | 69.835% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 96.29% |
| BioInvent International AB (publ) | -330.3 Million SEK | 96.328% |
| SynAct Pharma AB | -215.81 Million SEK | 94.38% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 72.47% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 48.907% |
| Alzinova AB (publ) | -16.48 Million SEK | 26.408% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 88.903% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 95.131% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -22.135% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 89.298% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 42.497% |
| Simris Alg AB (publ) | -37.3 Million SEK | 67.49% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 92.013% |